title: Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
abstract: OBJECTIVE
  To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjogren's syndrome (SS) and associated MALT lymphoma.
  
  
  METHODS
  The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m(2)) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.
  
  
  CONCLUSIONS
  Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. j.pijpe@kchir.azg.nl
authors.forename: J
authors.initials: J
authors.lastname: Pijpe
authors.forename: G W
authors.initials: GW
authors.lastname: van Imhoff
authors.forename: A
authors.initials: A
authors.lastname: Vissink
authors.forename: J E
authors.initials: JE
authors.lastname: van der Wal
authors.forename: P M
authors.initials: PM
authors.lastname: Kluin
authors.forename: F K L
authors.initials: FK
authors.lastname: Spijkervet
authors.forename: C G M
authors.initials: CG
authors.lastname: Kallenberg
authors.forename: H
authors.initials: H
authors.lastname: Bootsma
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D010306:Parotid Gland / Q000276:immunology / Q000503:physiopathology; D010307:Parotid Neoplasms / Q000188:drug therapy*; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab